CT screening for lung cancer is justified
Claudia I Henschke technology in general diagnostic use involving computer-aided diagnostic methods, including measurement of nodules. A portion of these royalties is distri buted to Dr Henschke and other coinventors pursuant to Cornell policy, which in turn is consistent with the Bayh-Dole Act. None of these technologies were required in performing any of the screenings described in the article nor was the technology discussed.
CORRIGENDUM
In the Viewpoint article by Claudia Henschke published in the August 2007 issue of Nature Clinical Practice Oncology, it was not disclosed at the time of publication that the author is a co-inventor on pending patents owned and filed by Cornell Research Foundation (CRF), a subsidiary of Cornell University, which are non-exclusively licensed to General Electric for doi:10.1038/ncponc1133
